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Abstract 
Heat shock proteins (HSPs) are induced in response to biological stress such as heat 
stress and chemical stress.  Heat shock protein 90 (HSP90) that is ubiquitously 
expressed in various tissues, is recognized to be a major molecular chaperone.  We 
have previously reported that prostaglandin F2α (PGF2α), a potent bone remodeling 
mediator, stimulates the synthesis of interleukin-6 (IL-6) through p44/p42 
mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like 
MC3T3-E1 cells, and that Rho-kinase acts at a point upstream of p38 MAP kinase.  In 
the present study, we investigated the involvement of HSP90 in the PGF2α-stimulated 
IL-6 synthesis and the underlying mechanism in MC3T3-E1 cells.  Geldanamycin, an 
inhibitor of HSP90, significantly amplified both the PGF2α-stimulated IL-6 release and 
the mRNA expression levels.  In addition, other HSP90 inhibitors, 
17-allylamino-17demethoxy-geldanamycin (17-AAG) and 
17-dimethylamino-ethylamino-17-demethoxy-geldanamycin (17-DMAG) and onalespib, 
enhanced the PGF2α-stimulated IL-6 release.  Geldanamycin, 17-AAG and onalespib 
markedly strengthened the PGF2α-induced phosphorylation of p38 MAP kinase.  
Geldanamycin and 17-AAG did not affect the PGF2α-induced phosphorylation of p44/p42 
MAP kinase and myosin phosphatase targeting subunit (MYPT-1), a substrate of 
Rho-kinase, and the protein levels of RhoA and Rho-kinase.  In addition, 
HSP90-siRNA enhanced the PGF2α-induced phosphorylation of p38 MAP kinase.  
Furthermore, SB203580, an inhibitor of p38 MAP kinase, significantly suppressed the 
amplification by geldanamycin, 17-AAG or 17-DMAG of the PGF2α-stimulated IL-6 
release.  Our results strongly suggest that HSP90 negatively regulates the 
PGF2α-stimulated IL-6 synthesis in osteoblasts, and that the effect of HSP90 is exerted 
through regulating p38 MAP kinase activation.  Therefore, HSP90 inhibitors might 
lead a new therapeutic strategy for acceleration of fracture healing and bone metabolic 
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diseases such as osteoporosis.  Further investigations would be required to clarify the 
details underlying the effects of HSP90 on bone metabolism. 
